Accepted Manuscript

Novel imidazo[2,1-*b*]-1,3,4-thiadiazoles as Promising Antifungal Agents Against Clinical Isolate of *C. Neoformans*

Wesam S. Alwan, Rajshekhar Karpoormath, Mahesh B. Palkar, Harun M. Patel, Rajesh A. Rane, Mahamadhanif S. Shaikh, Afsana Kajee, Koleka P. Mlisana

PII: S0223-5234(15)00188-9

DOI: 10.1016/j.ejmech.2015.03.021

Reference: EJMECH 7766

To appear in: *European Journal of Medicinal Chemistry*

Received Date: 3 October 2014

Revised Date: 9 March 2015

Accepted Date: 11 March 2015

Please cite this article as: W.S. Alwan, R. Karpoormath, M.B. Palkar, H.M. Patel, R.A. Rane, M.S. Shaikh, A. Kajee, K.P. Mlisana, Novel imidazo[2,1-*b*]-1,3,4-thiadiazoles as Promising Antifungal Agents Against Clinical Isolate of *C. Neoformans*, *European Journal of Medicinal Chemistry* (2015), doi: 10.1016/j.ejmech.2015.03.021.

Graphical Abstract

Novel Imidazo[2,1-*b*]-1,3,4-thiadiazoles as Promising Antifungal Agents Against Clinical Isolate of *C. Neoformans*

Wesam S. Alwan, Mahesh B. Palkar, Rajesh A. Rane, Harun M. Patel, Mahamadhanif S. Shaikh, Afsana Kajee, Koleka P. Mlisana, Rajshekhar Karpoormath[a*].

Abstract

Novel hybrids including chalcones (**5a-o**) and Schiff bases (**6a-j**) of imidazo[2,1-*b*]-1,3,4-thiadiazole scaffold were synthesized and evaluated against clinical isolate of *C. Neoformans* .



Designed analogues of Chalcones

`

Novel imidazo[2,1-*b*]-1,3,4-thiadiazoles as Promising Antifungal Agents Against Clinical Isolate of *C. Neoformans*

Wesam S. Alwan[a], , Rajshekhar Karpoormath[a*], Mahesh B. Palkar[a], Harun M. Patel[a], Rajesh A. Rane[a], Mahamadhanif S. Shaikh[a], Afsana Kajee[a], Koleka P. Mlisana[b]

[a]*Department of Pharmaceutical Chemistry, Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban – 4000, South Africa.*

[b]*Departemnt of Microbiology, National Health laboratory services (NHLS), Inkosi Albert Luthuli Central Hospital (Durban, South Africa).*

***Corresponding author**

E-mail: karpoormath@ukzn.ac.za, rvk2006@gmail.com

Tel no.: +27(0)312607179, +27721107207; Fax No.:+27(0)312607792

`

Abstract

We herein report the synthesis and *in vitro* antimicrobial evaluation of twenty five novel hybrid derivatives of imidazo [2,1-*b*]-1,3,4-thiadiazole containing chalcones (**5a-o**) and Schiff bases (**6a-j**) against three fungal strains (*Candida albicans*, *Cryptococcus neoformans* and *Aspergillus niger)*. Most of the tested compounds displayed substantial anti-fungal activity with MICs ranging between 1.56 - 100 µg/mL. Compounds **5a**, **5b** and **5n** exhibited promising activity against *Cryptococcus neoformans* at a MIC 1.56 µg/mL. In addition, compound **5n** also demonstrated significant antifungal activity against the clinical isolates of *Cryptococcus neoformans* at MIC 3.125 µg/mL. However, moderate activity was observed for these compounds against four bacterial strains (*Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli* and *Pseudomonas aeruginosa*) and *Mycobacterium tuberculosis* ($H_{37}Rv$).

Keywords: Imdazo [2,1-*b*]-1,3,4-thiadiazole; Chalcones, Schiff bases; Antifungal activity; *Cryptococcosis*; *C. neoformans*

`

1. Introduction

In the recent years, mortality and morbidity rate of opportunistic fungal infections is exponentially increasing and the number of fatal incidence due to fungi is becoming comparable with that of tuberculosis and malaria [1]. This could be attributed to increase in the number of patients with organ and stem cell transplantation, HIV/AIDS patients and other immune compromised patients [2]. Furthermore, the primary organisms responsible for invasive fungal infections (*e.g. Candida*, *Cryptococcus* and *Aspergillus* species) have developed drastic resistance. Patients with significant immunosuppression frequently develop *Cryptococcosis*, which is caused by the encapsulated yeast *Cryptococcus neoformans* and is responsible for serious clinical illnesses like lung infections, fungal meningitis and encephalitis [3]. It spreads by gulping aerosolized spores which may enter the pulmonary or the central nervous system [4]. Moreover, the virulence of *C. neoforman* depends upon the strain resistance and the immune level of the host, which could be latent and may lead to a permanent neurological injury [5-7]. A matter of grave concern in the treatment of fungal infections is the availability of limited number of efficacious antifungal drugs (*e.g.* amphotericin B, 5-fluorocytosine, fluconazole and voriconazole), which suffer from severe drawbacks such as; narrow therapeutic spectrum, drug resistance, high toxicity and low bioavailability [8, 9] . Although the use of a new generation of triazoles, the available polyenes in lipid formulations, the use of echinocandins or the combination therapy have been introduced as alternatives in the last ten years, but fungal infections still remains difficult to eradicate [10]. This necessitates urgent need to discover and develop novel chemotype antifungal molecules.

The fused ring of imidazole with a 1,3,4-thiadiazole motif is a very important heterocyclic system containing a bridgehead nitrogen atom known as imidazo[2,1-*b*]-1,3,4-thiadiazoles. Imidazo[2,1-*b*]-1,3,4 thiadiazoles are known to exhibit a diverse array of biological activities such as antibacterial

`

[11-13], anti-fungal (**I**) [14], anti- tubercular [15], anticonvulsant (**II**) [16, 17], antihyperlipidemic [18], anti-inflammatory (**III**), analgesic, antipyretic [19, 20], anti-cancer (**IV**), anthelmintic and anti ambeic agents[21]. Yet the cellular biology and the interactions of these compounds with different receptors and enzymes have not been widely studied [22]. Despite numerous attempts to develop new structural prototype in the search for more effective antimicrobials, the imidazo[2,1-*b*]-1,3,4-thiadiazole still remain as one of the most versatile scaffold, which could be further exploited to develop hybrids as promising antimicrobial agents.

On the other hand, the concept of hybrid drugs has gained more attention wherein two or more bioactive pharmacophores are linked covalently to have synergistic effect [23]. It is anticipated that such approach may solve the problem of drug resistance by displaying dual drug action [24]. Using this approach, several research groups have recently reported hybrid molecules by coupling medicinally privileged motif chalcone with biologically important pharmacophores. For instance an integration of coumarins with chalcones (**V**), led to hybrid compounds which displayed potent antitumor activity [25]. Likewise integration of Isatins with chalcones (**VI**) exhibited more efficacious activity than the commonly used chemotherapeutic drug cisplatin against the breast cancer cell lines [26]. Similarly, fusion of bromopyrrole alkaloid with chalcones (**VII**) demonstrated potent cytotoxicity and revealed that the integration of 4,5-dibromopyrrole moiety into chalcones lead to significant improvement of cytotoxic profile of 4,5-dibromopyrrole [27]. Correspondingly, chalcones bearing 2,4-thiazolidinedione and benzoic acid moieties (**VIII**) presented potential anti-bacterial activity against gram positive bacteria, particularly against multidrug-resistant strains of clinical isolates [28]. Moreover, integration of 5-nitroisoquinolines (**IX**) and Abacavir prodrugs (**X**) with Schiff bases enhanced the anti-malarial and anti-HIV scope of these compounds [29, 30]. Equally, integrating isoniazid a well-known anti-TB drug with aryl

`

hydrzone led to a hybrid (**XI**) which exhibited potent anti-tubercular activity [31]. Likewise, nitrofurantion hybrid (**XII**) with anti-infective activity was discovered by hybridizing 5-nitrofuran carboxyaldehyde motif with hydrazide feature [32] as illustrated in **Figure 1.** Therefore, in view of the above facts and in continuation of our search on biologically active hybrid molecules, herein we report the synthesis and spectral studies of novel chalcones (**5a-o**) and Schiff base (**6a-j**) hybrids of imidazo[2,1-*b*]-1,3,4-thiadiazoles with their subsequent *in vitro* biological evaluation for antibacterial, antifungal and anti-mycobacterial activity.

2. Chemistry

The synthesis of a series of novel chalcones (**5a-o**) and Schiff base (**6a-j**) hybrids of imidazo[2,1-*b*]-1,3,4-thiadiazole was achieved through convenient and efficient synthetic route as outlined in **Scheme 1**. Synthesis of the desired 2-substitutedphenyl-6-(4-bromophenyl)imidazo(2,1-*b*)1,3,4-thiadiazole (**3a-f**) was carried out by the condensation of 2-amino-5-substituted phenyl-1,3,4-thiadiazole (**2a-f**) with α-bromo ketone in DMF. Vilsmeier-Haack reaction of compounds (**3a-f**) with phosphurs oxychloride and DMF yielded the corresponding derivatives 2-substituted imidazo[2,1-*b*]- 1,3,4thiadiazole-5-carbaldehydes (**4a-f**) in good yields (85-90%). The aldehyde functional group at the 5th position of the imidazo[2,1-*b*]1,3,4-thiadiazole nucleus was utilized to perform Claisen-Schmidt reaction with different aryl/heteroaryl ketones in ethanolic NaOH (10%) to afford corresponding chalcone derivatives (**5a-o**). Compounds (**4a-f**) were further reacted with aliphatic cyclic amine using conventional method by refluxing in ethanol with catalytic amount of glacial acetic acid for 24 h. This resulted in lower yields of Schiff bases (**6a-j**) (10-20%). Thus, in order to improve the yield reactions were carried out under controlled microwave irradiation (*CEM* Discover, Explorer-*12 Hybrid, Microwave conditions:* 25 min at 150 psi*)*, which afforded the corresponding Schiff base (**6a-j**) in good yields (44-83 %) [11, 27].

`

3. Results and Discussion

Structures of compound (**4a-f**) and their corresponding final hybrid derivatives (**5a-o** and **6a-j**) were characterized based on their physicochemical and spectral (IR, ^{1}H NMR, ^{13}C NMR and MS,) analysis. The analytical data of all the newly synthesized compounds along with their anticipated structures are summarized in supporting information. The IR spectrum of compounds (**4a-e**) exhibited prominent and informative band, which appeared around 1757-1676 cm^{-1} indicating the presence of C=O (aldehydic carbonyl) group with confirming the formylation of compounds (**3a-e**) by Vilsmeier-Haack reaction. This was further substantiated from ^{1}H NMR spectra of compounds (**4a-f**), which exhibited a very distinct singlet peak resonating at δ10.14-10.09 ppm indicating the presence of aldehydic (CHO) proton, thus confirming the formation of imidazo[2,1-*b*]-1,3,4thiadiazoles-5-carbaldehydes. The formation of title chalcone derivatives (**5a-o**) is evident from their IR spectra, wherein the appearance of some prominent characteristic bands around 1674-1642 cm^{-1} due to C=O stretch (chalcone), 1590-1406 cm^{-1} for C=C stretch (α-β unsaturated carbons of chalcone) and 810.2-679 cm^{-1} for C-Br Str. The ^{1}H NMR spectra of compounds (**5a-o**) revealed two distinctive doublets at δ 8.38-8.17 ppm and δ 8.09-8.03 ppm with coupling constant (*J*) of 14-16 Hz, indicating the presence of α and *β* unsaturated protons of chalcones, while the various aromatic protons appeared around δ 7.90-7.05 ppm.

The formation of imines (**6a-j**) was confirmed by IR spectra, where the disappearance of strong band around 1757-1676 cm^{-1} of C=O group and appearance of characteristic imine (HC=N Str) band between 1671-1561 cm^{-1}. Further, the ^{1}H NMR spectra of Schiff base compounds (**6a-j**) displayed a prominent singlet signal resonating around δ 8.64-7.97 ppm, which was attributed to imine proton (CH=N), while the aromatic/heteroaromatic protons appeared as doublets/multiplet signals between δ 8.14-6.96 ppm. In ^{13}C NMR spectrum, it was observed that the most characteristic carbon signals

`

(CH_3, OCH_3, -CH=CH- and C=O) appeared at around δ 21.6, 55.6, 150-138.0 and 190.1-181.8 ppm respectively, while the signals observed at around δ 121.5-114.4, 138.5-132.0, 145.9-138.3, 149.9-145.7 ppm were assigned to C-5, C-7a, C-2, C-6. The aromatic carbon peaks appeared around δ 135.0-120.0 ppm, whereas the aliphatic cyclopropyl and/or cyclohexyl carbons resonated between δ 70.4-8.1 ppm. In addition, the formation of title compounds was also confirmed by recording their respective mass spectra, which were in agreement with their expected molecular weights.

The Chalcone (**5a**-**o**) and Schiff base (**6a**-**j**) derivatives of imdazo[2,1-*b*]-1,3,4-thiadiazole scaffold were evaluated for their *in vitro* antifungal activity against *Candida albicans* ATCC90028, *Cryptococcus neoformans* ATCC6603 and *Aspergillus niger* ATCC16404, where Amphotericin B was used as reference drug. The results (MIC values) of *in vitro* antifungal screening of the test compounds are summarized in **Table 1**. However, a systematic analysis of the data as depicted in **Table 1** revealed that compounds **5a**, **5b** and **5n** exhibited comparable antifungal activity (MICs = 1.56 µg/mL), against *Cryptococcus neoformans* as the standard drug Amphotericin B (MIC = 1-2 µg/mL).

Compounds **5a**, **5b** and **5n** exhibited most promising activity against *C. neoformans* at a MIC 1.56 µg/mL while compounds **5c**, **5k** and **5m** were moderately active at a MIC 3.125 µg/mL. Compound **6d** (MIC = 12.5 µg/mL) showed moderate antifungal activity against *C. albicans*. Further, all the synthesized compounds were tested against two well characterized clinical isolates of fungal strains *C. albicans* and *C. neoformans*. The antifungal activity on the clinical isolates was carried out at the Department of Microbiology, Inkosi Albert Luthuli Hospital, Durban, South Africa. Among the tested series, compound **5n** (MIC = 3.125 µg/mL) exhibited good antifungal activity against clinical isolate of *C. neoformans*, while compounds **5a**, **5i** and **5k** displayed moderate activity with MIC of 6.25 µg/mL. In general, *para* and *meta* substitution on ring A with electron withdrawing (bromo and

`

chloro), electron donating (methoxy) groups and presence of *para* bromo group on the phenyl group of Ring B were observed to be beneficial feature for the antifungal activity. In case of Chalcones, Ring C was tolerated to be unsubstituted phenyl and *p*-methyphenyl (*p*-CH_3-C_6H_4) for antifungal activity. The presence of heteroaryl group such as thiophene at ring C was not favored for the antifungal activity. In case of Schiff bases, the presence of cyclic propyl or hexyl group exhibited good antifungal activity. From literature, imidazo[2,1-*b*]-1,3,4-thiadiazoles derivatives were reported for the antibacterial and anti-mycobacterial activity [13, 33, 34]. Hence, the synthesized compounds were evaluated against Gram positive; *Staphylococcus aureus* ATCC25923, *Bacillus subtilis* ATCC605 and Gram negative; *Escherichia coli* ATCC35218, *Pseudomonas aeruginosa* ATCC27853] bacterial strain and *M. tuberculosis* H_{37}Rv strain. The antituburcular activity of these compounds were carried out at National Institute of Allergy and Infectious Diseases (NIAID) screening program, Bethesda, MD, USA [29-32]. All the synthesized compounds displayed moderate or no activity against bacterial and mycobacterial strain as depicted in **Table 1.**

4. Conclusion

In conclusion, twenty five novel hybrids including chalcones (**5a**-**o**) and Schiff bases (**6a**-**j**) of imidazo[2,1-*b*]-1,3,4-thiadiazole scaffold were synthesized and evaluated for their antifungal, antitubercular and antibacterial activity. These synthesized hybrids displayed promising activity against tested fungal strains, in particular for both the normal and clinical isolate of *C. neoformans*. The chalcone (**5a**-**o**) derivatives exhibited significant antifungal activity when compared to the Schiff bases (**6a**-**j**). The antifungal activity displayed by compounds **5a, 5b** and **5n** against *Cryptococcus neoformans* indicates that these substituted hybrids can act as leads and can be further exploited to develop potential antifungal agents. In addition, these active chalcones of

`

imidazothiadiazole (**5a-o**) also displayed moderate activity (MIC >20 µg/mL) against *M. tuberculosis* $H_{37}Rv$. The encouraging antifungal and anti-mycobacterial activity of synthesized novel imidazo [2,1-*b*]-1,3,4-thiadiazole derivatives through modification of ring substituents and/or additional functionalization indicated the potential for further research into the development antifungal agents against the resistant clinical isolates.

5. Experimental Section

The analytical grade (AR) chemicals and reagents procured from commercial suppliers (Merck and Sigma-Aldrich) and used without further purification. The solvents except AR grade were purified as per the literature methods when necessary. The progress of the reactions and the purity of the synthesized compounds were monitored by thin layer chromatography using pre-coated silica gel plates (Merck), UV light and/or Iodine vapors were used as visualization agents. Melting points were determined in open capillaries using (Electrothermal 9300) digital melting point apparatus and were uncorrected. The IR spectra were recorded on (Perkin Elmer 100) FT-IR spectrophotometer with universal ATR sampling accessory. ^{1}H and ^{13}C NMR spectra were recorded on (Bruker Advance IV) NMR spectrometer at 400 and 100 MHz respectively using $CDCl_3$ and DMSO-d_6. (CEM *Discover, Explorer*-12 Hybrid) Microwave reactor was used to synthesize some Schiff base derivatives.

5.1 General procedure for the synthesis of 2-amino-5-substitutedphenyl 1,3,4-thiadiazole (2a-f)

The each substituted benzoic acid (6.001g, 0.05 mol), thiosemicarbazide (4.557 g, 0.05 mol) and $POCl_3$ (13 ml) were thoroughly stirred, mixed and heated at 75°C for 1 h with constant stirring. After cooling to rt, water (40 ml) was slowly added. The reaction mixture was further refluxed for 4h. After cooling, the mixture was basified to pH 8 by careful drop wise addition of 10% aqueous

`

ammonia solution with constant stirring. The precipitate thus obtained was filtered and recrystallized from ethanol: water mixture to yield the pure compounds (**2a-e**) [13].

5.2 General procedure for the synthesis of 2-substitutedphenyl-6-(4-bromophenyl) imidazo(2,1-b)1,3,4-thiadiazole (3a-f)

A mixture of equimolar quantities of 2-amino-5-substitutedphenyl 1,3,4-thiadiazole (2g, 0.0078 mol) and 4-bromo phenacylbromide (2.1g, 0.0078 mol) was heated for 12-16 h with constant stirring in DMF (10 ml). The reaction mixture was poured onto crushed ice and the solid hydrobromide separated was filtered, washed and dried. Neutralization of hydrobromide salt intermediate with cold aqueous solution of sodium carbonate yielded the corresponding free bases (**3a-f**), which were further purified by recrystallization from ethanol[11].

5.3 General procedure for the synthesis of 2-substitutedphenyl-5-formyl-6-(4-bromophenyl) imidazo(2,1-b)1,3,4-thiadiazole (4a-f)

Vilsmeier-Haack reagent was freshly prepared by the careful addition of phosphoryl chloride (2ml, 0.021 mol) in DMF (8 ml, 0.103 mol) at 0 °C with constant stirring. Then an appropriately 2-substitutedphenyl-6-(4-bromophenyl)imidazo(2,1-*b*)1,3,4-thiadiazole (2g, 0.0045 mol) was added to the reagent with continuous stirring maintaining the temperature at 0 °C for initial 30 min and later stirred at rt for 2 h, and finally at 60 °C for another 2 h. The reaction mixture was then poured in sodium carbonate solution and stirring was continued at 90 °C for 2 h. After cooling to rt, the reaction mixture was suspended into water, extracted with (20 ml) dichloromethane (3 times), and the collective extracts were washed with water and dried over anhydrous sodium sulphate. The residue obtained after the in-vacuo removal of dichloromethane was further recrystallized from ethanol to afford the desired compound (**4a-f**) as colourless crystalline solid [35].

`

5.4 General procedure for the synthesis of 3-(2-(2-substitutedphenyl)-6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-substituted aryl/heteroaryl-prop-2-en-1-one (5a-o)

In a round bottom flask equipped with sealed mechanical stirrer, 10% sodium hydroxide solution (2 ml) and (10 ml) ethanol were constantly stirred in an ice-bath for 2 min. Then, the appropriately substituted aryl/heteroaryl ketones (0.3 g, 0.002 mol) and compounds (**4a-f**) (1 g, 0.002 mol) were slowly added to the above mixture and stirred for 30 min. The reaction mixture was further stirred at rt for 6-10 h. The solid precipitate obtained was filtered, dried and recrystallized using ethanol to yield the chalcone derivatives (**5a-o**) of imidazo [2,1-*b*][1,3,4]thiadiazoles [27].

5.4.1 3-(2-(2-bromophenyl)-6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1 phenylprop-2-en-1-one 5a.

Yellow crystals; Yield 79%, mp. 231-233 °C; IR [ATR, ν_{max}, cm^{-1}]: 3054.1(Ar C-H), 3001.4 (C=C-H), 1723.8 (C=N), 1661.3 (C=O), 1590 (C=C), 687.2 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.37-8.33 (d, *J* = 15 Hz, 1H, H *β*), 8.09-8.07 (d, *J* = 15 Hz, 1H, H*α*), 8.06-8.05 (m, 1H, Ar-H), 7.92-7.90 (m, 1H, Ar-H), 7.85-7.83 (m, 1H, Ar-H), 7.69-7.54 (m, 4H, Ar-H), 7.52-7.46 (m, 6H, Ar-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 189.9, 160.3, 150.0, 149.4, 138.3, 134.8, 132.8, 132.6, 132.3, 132.1, 132.1, 131.8, 130.3, 130.2, 129.7, 129.7, 128.8, 128.6, 128.5, 128.2, 128.1, 123.2, 122.1, 121.5, 120.2; HRMS (EI) *m/z* calcd for $C_{25}H_{15}Br_2N_3OS$: 562.9303; found: 562.9308.

5.4.2 3-(2-(2-bromophenyl)-6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-p-tolylprop-2-en-1-one 5b.

Yellow crystals; Yield 56%, mp. 225-227 °C; IR [ATR, ν_{max}, cm^{-1}]: 3057.8 (Ar C-H), 2923.8 (C=C-H), 1728 (C=N), 1658.9 (C=O), 1587.3 (C=C), 687.2 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.37-8.33 (d, *J* = 15 Hz, 1H, H *β*), 8.08-8.04 (d, *J* = 15, 1H, H *α*), 8.01-7.99 (m, 2H, Ar-H), 7.92-

`

7.83 (m, 2H, Ar-H), 7.69-7.63 (m, 4H, Ar-H), 7.56-7.44 (m, 2H, Ar-H), 7.31-7.29 (m, 2H, Ar-H), 2.43 (s, 3H, Ar-CH_3); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 189.4, 160.2, 149.8, 149.3, 143.6, 135.7, 134.8, 132.5, 132.4, 132.1, 131.8, 130.5, 130.3, 129.1, 129.6, 129.3, 129.1, 129.1, 128.6, 128.1, 127.8, 123.2, 122.1, 121.5, 120.4, 21.6; HRMS (EI) *m/z* calcd for $C_{26}H_{17}Br_2N_3OS$: 576.9459; found: 576.9463.

5.4.3 3-(2-(2-bromophenyl)-6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one 5c.

Yellow crystals; Yield 53%, mp. 263-265 °C; IR [ATR, ν_{max}, cm^{-1}]: 3064.6 (Ar C-H), 2962.7 (C=C-H), 1724.4 (C=N), 1647.3 (C=O), 1578.6 (C=C), 707.3(C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.21-8.17 (d, *J* = 15 Hz, 1H, H *β*), 8.06-8.02 (d, *J* = 15, 1H, H*α*), 8.89-7.61 (m, 8H, Ar-H), 7.56-7.52 (m, 1H, thiophene 3H), 7.47-7.42 (m, 1H, thiophene 4H), 7.17-7.15 (m, 1H, thiophene 5H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 181.9, 160.3, 150.1, 149.4, 145.9, 134.8, 134.1, 133.7, 132.6, 132.3, 132.1, 131.8, 131.7, 130.3, 130.2, 129.7, 128.2, 128.1, 127.5, 123.3, 122.1, 121.3, 120.1; HRMS (EI) *m/z* calcd for $C_{23}H_{13}Br_2N_3OS_2$: 568.8867; found: 568.8871.

5.4.4 3-(6-(4-bromophenyl)-2-(2-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-phenylprop-2-en-1-one 5d.

Yellow crystals; Yield 62%, mp. 223-225 °C; IR [ATR, ν_{max}, cm^{-1}]: 3064.5(Ar C-H), 2601.3 (C=C-H), 1714.6 (C=N), 1654.7 (C=O), 1586 (C=C), 687.5 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.34-8.30 (d, *J* = 16 Hz, 1H, H β), 8.07-8.05 (d, *J* = 15, 1H, H α), 8.04-7.98 (m, 3H, Ar-H), 7.66-7.52 (m, 5H, Ar-H), 7.51-7.46 (m, 5H, Ar-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 189.9, 159.1, 150.1, 149.5, 138.3, 132.8, 132.8, 132.7, 132.4, 132.1, 132.1, 131.4, 131, 131, 130.2, 128.6, 128.6, 128.4, 128.2, 128.2, 127.6, 124.5, 123.2, 121.3, 120.2; HRMS (EI) *m/z* calcd for $C_{25}H_{15}BrClN_3OS$: 518.9808; found: 518.9812.

`

5.4.5 3-(6-(4-bromophenyl)-2-(2-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-p-tolylprop-2-en-1-one 5e.

Yellow crystals; Yield 78%, mp. 236-238 °C; IR [ATR, ν_{max}, cm^{-1}]: 3054.6 (Ar C-H),2599.9 (C=C-H), 1731.4 (C=N), 1658.6 (C=O), 1587.7 (C=C), 756.9 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.34-8.30 (d, *J* = 16 Hz, 1H, H β), 8.06-8.05 (d, *J* = 15, 1H, H α), 8.03-7.98 (m, 3H, Ar-H), 7.66-7.60 (m, 5H, Ar-H),7.52-7.48 (m, 2H, Ar-H), 7.30-7.28 (d, 2H, Ar-H), 2.42 (s, 3H, Ar-CH3); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 189.4, 159.0, 149.9, 149.4, 143.6, 135.8, 132.4, 132.1, 132.1, 131.4, 131, 131, 130.1, 130.1, 129.3, 129.3, 128.6, 128.6, 127.8, 127.8, 127.6, 127.6, 123.2, 121.4, 120.3. 21.7; HRMS (EI) *m/z* calcd for $C_{26}H_{17}BrClN_3OS$: 532.9964; found: 532.9968.

5.4.6 3-(6-(4-bromophenyl)-2-(2-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one 5f.

Yellow crystals; Yield 86%, mp. 260-263 °C; IR [ATR, ν_{max}, cm^{-1}]: 3062.4(Ar C-H), 2585.1 (C=C-H), 1899.3 (C=N), 1646.9 (C=O), 1584.5 (C=C), 725.8 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.23-8.19 (d, *J* = 15 Hz, 1H, H β),8.09-8.07 (d, *J* = 15, 1H, Hα), 8.06-8.04 (m, 1H, Ar-H), 7.89-7.88 (m, 1H, Ar-H),7.67-7.63 (m, 1H, Ar-H), 7.55-7.52 (m, 2H, thiophene 3H,4H), 7.20-7.18 (m, 1H thiophene, 5H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 181.9, 159.1, 150.2, 145.8, 133.6, 132.8, 132.4, 132.1, 131.8, 131.6, 131.4, 131, 130.2, 129.7, 129.7, 128.2, 128.2, 127.6, 127.5, 125, 123.3, 121.1, 120.1; HRMS (EI) *m/z* calcd for $C_{23}H_{13}BrClN_3OS_2$: 524.9372; found: 524.9376.

5.4.7 3-(6-(4-bromophenyl)-2-phenylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-phenylprop-2-en-1-one 5g.

Yellow crystals; Yield 53%, mp. 263-265 °C; IR [ATR, ν_{max}, cm^{-1}]: 3064 (Ar C-H), 1655.3 (C=O), 1572.5 (C=C), 690 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.29-8.25 (d, *J* = 15 Hz, 1H, H β), 8.03-8.00 (d, *J* = 15, 1H, Hα), 7.96-7.89 (m, 4H, Ar-H), 7.60-7.56 (m, 5H, Ar-H), 7.51-7.40 (m, 5H,

`

Ar-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 190.0, 162.7, 149.8, 148.6, 138.4, 132.7, 132.2, 132.2, 132.2, 132.1, 132.1, 130.1, 130.1, 130.1, 129.5, 129.5 , 128.7, 128.7, 128.4, 128.4, 128.3, 126.9, 123.1, 121.6, 120.3; HRMS (EI) *m/z* calcd for $C_{25}H_{16}BrN_3OS$: 485.0197; found: 485.0201.

5.4.8 3-(6-(4-bromophenyl)-2-phenylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-p-tolylprop-2-en-1-one 5h.

Yellow crystals; Yield 80%, mp. 244-246 °C; IR [ATR, ν_{max}, cm^{-1}]: 3033.1 (Ar C-H), 1655.6 (C=O), 1582.9 (C=C), 688.8 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.38-8.34 (d, *J* = 15 Hz, 1H, H β),8.08-8.04 (d, *J* = 15, 1H, Hα), 8.02-7.92 4 (m, 4H, Ar-H), 7.67-7.66 (m, 3H, Ar-H), 7.62-7.60 (m, 4H, Ar-H), 7.37-7.35 (m, 2H, Ar-H), 2.48 (s, 3H, Ar-CH3); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 189.5, 162.6, 148.5, 143.6, 135.8, 132, 132, 131.9, 131.9, 130.5, 130.5, 130.1, 130.1, 129.5, 129.46, 129.41, 128.6, 128.6, 127.9, 127.9, 126.9, 126.9, 123.1, 121.6, 120.5, 21.7; HRMS (EI) *m/z* calcd for $C_{26}H_{18}BrN_3OS$: 499.0354; found: 499.0358.

5.4.9 3-(6-(4-bromophenyl)-2-phenylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one 5i.

Yellow crystals; Yield 66%, mp. 267-269 °C; IR [ATR, ν_{max}, cm^{-1}]: 3074.7 (Ar C-H), 1642.6 (C=O), 1575.6 (C=C), 685.3 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.21-8.17 (d, *J* = 15 Hz, 1H, H β), 8.04-8.01 (d, *J* = 15, 1H, H α), 7.97-7.95 (m, 2H, Ar-H), 7.90-7.88 (m, 1H, Ar-H),7.69-7.68 (m, 1H, Ar-H), 7.62-7.59 (m, 3H, Ar-H), 7.58-7.57 (m, 2H, thiophene 3H,4H), 7.22-7.20 (m, 1H, thiophene 5H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 181.8, 162.7, 149.8, 148.6, 145.8, 133.6, 132.3, 132.3, 132.2, 132.2, 132.1, 131.5, 131.5, 130.1, 130.1, 129.8, 129.5, 129.5, 128.3, 127.6, 126.9, 123.2, 121.4; HRMS (EI) *m/z* calcd for $C_{23}H_{14}BrN_3OS_2$: 490.9762; found: 490.9766.

`

5.4.10 3-(6-(4-bromophenyl)-2-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-phenylprop-2-en-1-one 5j.

Yellow crystals; Yield 64%, mp. 247-250 °C; IR [ATR, ν_{max}, cm^{-1}]: 3063.5 (Ar C-H), 1656.9 (C=O), 1572.6 (C=C), 679.3 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.29-8.25 (d, *J* = 15 Hz, 1H, H β), 8.07-8.05 (d, *J* = 15, 1H, H α), 8.04-8.00 (m, 2H, Ar-H), 7.90-7.88 (d, *J* =8.56 Hz, 2H, Ar-H), 7.62-7.56 (m, 5H, Ar-H), 7.54-7.50 (m, 4H, Ar-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 190, 161.4, 149.9, 148.7, 138.5, 138.3, 132.8, 132.8, 132.2, 132.2, 132.1, 132.1, 130.1, 129.9, 129.9, 128.9, 128.9, 128.7, 128.7, 128.4, 128.3, 128.1, 123.2, 121.6, 120.5; HRMS (EI) *m/z* calcd for $C_{25}H_{15}BrClN_3OS$: 518.9808; found: 518.9812.

5.4.11 3-(6-(4-bromophenyl)-2-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-p-tolylprop-2-en-1-one 5k.

Yellow crystals; Yield 50%, mp. 246-248 °C; IR [ATR, ν_{max}, cm^{-1}]: 2915.3 (Ar C-H), 1658.5 (C=O), 1586.7 (C=C), 810.2 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.29-8.25 (d, *J* = 15 Hz, 1H, H β), 8.03-7.99 (d, *J* = 15, 1H, Hα), 7.98-7.96 (d, *J* =8.12 Hz, 2H, Ar-H), 7.90-7.87 (d, *J* = 8.60 Hz, 2H, Ar-H), 7.62-7.60 (m, 4H, Ar-H), 7.56-7.54 (d, *J* =8.48 Hz, 2H, Ar-H), 7.33-7.31(d, *J* =8.08 Hz, 2H, Ar-H), 2.44 (s, 3H, Ar-CH3); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 189.5, 161.3, 149.6, 148.2, 143.7, 138.4, 135.8, 132.3, 132.1, 132.1, 131.8, 130.1, 130.1, 129.8, 129.4, 129.4, 129.2, 129, 128.5, 128.3, 128. 127.8, 123.1, 121.6, 120.6, 21.6; HRMS (EI) *m/z* calcd for $C_{26}H_{17}BrClN_3OS$: 532.9964; found: 532.9968.

5.4.12 3-(6-(4-bromophenyl)-2-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one 5l.

Yellow crystals; Yield 45%, mp. 266-268 °C; IR [ATR, ν_{max}, cm^{-1}]: 3341.2 (Ar C-H), 1645.4 (C=O), 1406 (C=C), 719.2 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.17-8.13 (d, *J* = 15 Hz,

`

1H, H β), 8.04-8.00 (d, *J* = 15, 1H, Hα), 7.91-7.87 (m, 3H, Ar-H), 7.69-7.62 (m, 5H, Ar-H), 7.59-7.55 (m, 2H, thiophene 3H,4H), 7.22-7.20 (t, *J* = 8.68 Hz , 1H, thiophene 5H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 181.8, 161.4, 149.9, 148.4, 145.7, 138.5, 133.6, 132.2, 132.1, 132.1, 131.8, 131.5, 130.1, 129.9, 129.5, 129.3, 128.3, 128, 127.9, 127.5, 123.3, 121.44, 120.4; HRMS (EI) *m/z* calcd for $C_{23}H_{13}BrClN_3OS_2$: 524.9372; found: 524.9376.

5.4.13 3-(6-(4-bromophenyl)-2-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-phenylprop-2-en-1-one 5m.

Pale Yellow crystals; Yield 52%, mp. 229-231 °C; IR [ATR, ν_{max}, cm^{-1}]: 2964.7 (Ar C-H), 1652.6 (C=O), 1563.8 (C=C), 818.8 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.32-8.28 (d, *J* = 15 Hz, 1H, H β), 8.08-8.04 (m, 2H, Ar-H), 8.04-8.00 (d, *J* = 15, 1H, H α), 7.89-7.87 (d, *J* =8.88 Hz, 2H, Ar-H), 7.64-7.50 (m, 7H, Ar-H), 7.06-7.03 (d, *J* = 8.84 Hz, 2H, Ar-H), 3.92 (s, 3H, Ar-OCH3); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 190.1, 162.8, 162.5, 149.5, 148.5, 138.4, 132.7, 132.4, 132, 132, 130.1, 130.1, 128.7, 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 123, 122.3, 121.5, 120.1, 114.9, 55.6; HRMS (EI) *m/z* calcd for $C_{26}H_{18}BrN_3O_2S$: 515.0303; found: 515.0308.

5.4.14 3-(6-(4-bromophenyl)-2-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-p-tolylprop-2-en-1-one 5n.

Yellow crystals; Yield 72%, mp. 252-254 °C; IR [ATR, ν_{max}, cm^{-1}]: 2939.2 (Ar C-H), 1654.6 (C=O), 1581.9 (C=C), 764.3 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.32-8.28 (d, *J* = 15 Hz, 1H, H β), 8.03-8.00 (d, *J* = 13 Hz, 1H, H α), 7.99-7.98 (d, *J* = 5.76 Hz, 2H, Ar-H), 7.89-7.87 (d, *J* =8.7 Hz, 2H, Ar-H), 7.64-7.59 (q, *J* = 4.2 Hz, 4H, Ar-H), 7.33-7.31 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.06-7.04 (d, *J* = 4.84 Hz, 2H, Ar-H), 3.9 (s, 3H, Ar-OCH3), 2.46 (s, 3H, Ar-CH3); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 189.6, 162.7, 149.3, 143.5, 135.9, 132, 132, 131.7, 131.7, 130.1, 130.1, 130.1,

`

129.4, 129.4, 129.1, 129.1, 128.5, 128.5, 128.1, 128.1, 123, 122.4, 121.5, 120.3, 114.9, 55.6, 21.7; HRMS (EI) *m/z* calcd for $C_{27}H_{20}BrN_3O_2S$: 529.0460; found: 529.0464.

5.4.15 3-(6-(4-bromophenyl)-2-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one 5o.

Orange crystals; Yield 57%, mp. 257-259 °C; IR [ATR, ν_{max}, cm^{-1}]: 3063.7 (Ar C-H), 1674 (C=N), 1647 (C=O), 1579.9 (C=C), 716.5 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.19-8.16 (d, *J* = 15 Hz, 1H, H β), 8.03-7.99 (d, *J* = 15 Hz, 1H, H α), 7.90-7.87 (m, 3H, Ar-H), 7.64-7.59 (m, 5H, Ar-H), 7.22-7.19 (m, 1H, thiophene 3H), 7.07-7.05 (d, *J* = 8.76 Hz, 2H, thiophene 4H,5H), 3.9 (s, 3H Ar-OCH3); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 181.9, 162.8, 162.5, 149.6, 148.6, 145.8, 133.6, 132.4, 132, 131.8, 131.5, 130.1, 129.5, 128.5, 128.4, 128.3, 127.7, 123.1, 122.3, 121.3, 120, 114.9, 114.4, 55.6; HRMS (EI) *m/z* calcd for $C_{24}H_{16}BrN_3O_2S_2$: 520.9867; found: 520.9871.

5.5 General procedure for the synthesis of 6-(4-bromophenyl)-2-(substitutedphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)cyclosubstitutedamine (6a-j)

Compounds **(4a-f)** (0.2 g, 0.0003 mol) and aliphatic cyclic amine (0.025g, 0.0003 mol) in ethanol (5 ml) and catalytic amount of glacial acetic acid were transferred into a 10 mL microwave tube kitted with mechanical stirrer. The reaction mixture was irradiated with microwave radiations for 20-30 min at 150 psi pressure. The completion of reaction was monitored by TLC using ethyl acetate and hexane (1:3). The solid thus obtained was filtered, dried and recrystallized using the suitable solvent to afford the Schiff base derivatives (**6a-j**) of imidazo [2, 1-*b*][1,3,4]thiadiazoles.

5.5.1 2-(2-bromophenyl)-6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)cyclopropanamine 6a.

Yellow crystals; Yield 45%, mp. 204-206 °C; IR [ATR, ν_{max}, cm^{-1}]: 3136.9 (Ar C-H), 3064.7 (C=C-H), 1561.4 (CH=N), 749.6 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.06 (s,1H,CH=N), 7.84-

`

7.82 (m, 1H, Ar-H), 7.74-7.70 (m, 3H, Ar-H), 7.53-7.45 (d, *J*= 8.25 Hz, 2H, Ar-H), 7.43-7.39 (m, 1H, Ar-H), 7.37-7.35 (m, 1H, Ar-H), 1.71 (br s, 4 H, Aliphatic-H), 1.23 (s, 1H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 159.5, 146.5, 145.7, 134.3, 132.8, 132.2, 132.2, 132.2, 131.8, 131.7, 130.7, 127.9, 127.9, 126.7, 122, 121.5, 109.3, 29.6, 10.2, 10.2; HRMS (EI) *m/z* calcd for $C_{20}H_{14}Br_2N_4S$: 499.9306; found: 499.9310.

5.5.2 2-(2-bromophenyl)-6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)cyclohexanamine 6b.

Orange crystals; Yield 60%, mp. 197-199 °C; IR [ATR, ν_{max}, cm^{-1}]: 3063.3 (Ar C-H), 2852.8 (C=C-H), 1639.1 (CH=N), 752.5 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.64 (s, 1H, CH=N), 7.94-7.92 (m, 3H, Ar-H), 7.74-7.72 (m, 1H, Ar-H), 7.57-7.55 (m, 2H, Ar-H), 7.39-7.37 (m, 1H, Ar-H), 1.81-1.77 (m, 4H, Aliphatic-H), 1.65-1.60 (m, 3H, Aliphatic-H), 1.38-1-30 (m, 4H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 160.1, 147.2, 146.2, 134.3, 132.6, 132.3, 132.1, 132, 131.5, 130.7, 130.5, 130.2, 128, 127.9, 122.6, 122.1, 121.9, 70.4, 34.4, 25.6, 25.1, 24.65, 24.60; HRMS (EI) *m/z* calcd for $C_{23}H_{20}Br_2N_4S$: 541.9775; found: 541.9779.

5.5.3 6-(4-bromophenyl)-2-(2-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl) methylene)cyclopropanamine 6c.

Yellow crystals; Yield 50%, mp. 189-191 °C; IR [ATR, ν_{max}, cm^{-1}]: 3136.8 (Ar C-H), 3068.2 (C=C-H), 1648.5 (CH=N), 750 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.06 (s, 1H, CH=N), 8.00-7.98 (m, 1H, Ar-H), 7.72-7.69 (d, *J* = 8.48 Hz, 2H, Ar-H), 7.53-7.45 (m, 3H, Ar-H), 7.43-7.39 (m, 2H, Ar-H), 1.77 (s, 4H, Aliphatic-H), 1.23 (s, 1H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 158.2, 146.7, 145.8, 132.8, 132.6, 132.1, 132.1, 132.1, 131.8, 131, 130.9, 128.6, 128.6, 127.4, 126.7, 121.5, 109.2, 29.7, 11.2, 11.2; HRMS (EI) *m/z* calcd for $C_{20}H_{14}BrClN_4S$: 455.9811; found: 455.9815.

`

5.5.4 6-(4-bromophenyl)-2-(2-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl) methylene)cyclohexanamine 6d.

Yellowish green crystal; Yield 70%, mp. 188-190 °C; IR [ATR, ν_{max}, cm^{-1}]: 3056.4 (Ar C-H), 2849.8 (C=C-H), 1637.9 (CH=N), 747.2 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.68 (s, 1H, CH=N), 8.14-8.00 (m, 1H, Ar-H), 7.95-7.93 (d, *J* = 8.25 Hz, 2H, Ar-H), 7.57-7.53 (m, 2H, Ar-H), 7.45-7.40 (m, 3H, Ar-H), 1.85-1.78 (m, 4H, Aliphatic-H), 1.66-1.61 (t, *J* = 11.48 Hz, 3H, Aliphatic-H), 1.39-1.34 (m, 4H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 158.7, 147.9, 147.3, 146.2, 132.7, 132.6, 132.1, 132.1, 131.4, 131.2, 130.9, 130.2, 128.6, 128.6, 127.4, 122.6, 121.8 70.4, 34.4, 25.7, 25.7, 25.7, 24.5; HRMS (EI) *m/z* calcd for $C_{23}H_{20}BrClN_4S$: 498.0281; found 498.0285.

5.5.5 6-(4-bromophenyl)-2-phenylimidazo[2,1-b][1,3,4]thiadiazol-5- yl)methylene) cyclopropanamine 6e.

Yellowish green crystals; Yield 83%, mp. 190-192 °C; IR [ATR, ν_{max}, cm^{-1}]: 3117.5 (Ar C-H), 2923 (C=C-H), 1671.4 (CH=N), 760.1 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.02 (s, 1H, CH=N), 7.87 – 7.84 (d, *J* = 8.40 Hz, 2H, Ar-H), 7.70-7.68 (d, *J* = 8.56 Hz, 2H, Ar-H), 7.52-7.49 (m, 5H, Ar-H), 1.64 (br s, 3H, Aliphatic-H), 1.23-120 (m, 2H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 161.7, 145.5, 145.4, 132.8, 131.8, 131.8, 131.7, 131.7, 130.1, 130.1, 129.3, 129.3, 129.3, 126.7, 126.6, 121.4, 109.5, 32.5, 8.1, 8.1; HRMS (EI) *m/z* calcd for $C_{20}H_{15}BrN_4S$: 422.0201; found 422.0205.

5.5.6 6-(4-bromophenyl)-2-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5- yl)methylene) cyclopropanamine 6f.

Yellow crystals; Yield 52%, mp. 187-189 °C; IR [ATR, ν_{max}, cm^{-1}]: 3056 (Ar C-H), 2847.6 (C=C-H), 1640.3 (CH=N), 761.3(C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.01 (s, 1H, CH=N), 7.80-7.78 (d, *J* = 8.60 Hz, 2H, Ar-H), 7.69-7.67 (d, *J* = 8.56 Hz, 2H, Ar-H), 7.52-7.46 (m, 4H, Ar-H),

`

1.61 (br s, 4H, Aliphatic-H), 1.22 (s, 1H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 160.4, 145.7, 145.3, 137.9, 132.6, 131.8, 131.8, 131.6, 129.6, 129.6, 128.6, 128.6, 127.9, 127.9, 126.6, 121.5, 109.5, 50.8, 30.9, 30.9; HRMS (EI) *m/z* calcd for $C_{20}H_{14}BrClN_4S$: 455.9811; found 455.9815.

5.5.7 6-(4-bromophenyl)-2-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene) cyclohexanamine 6g.

Yellowish green crystal; Yield 61%, mp. 238-240 °C; IR [ATR, ν_{max}, cm^{-1}]: 3147.2 (Ar C-H), 2848.3 (C=C-H), 1652 (CH=N), 730.9(C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.62 (s, 1H, CH=N), 7.93-7.90 (d, *J* = 8.64 Hz, 2H, Ar-H), 7.86-7.84 (d, *J* = 8.52 Hz, 2H, Ar-H), 7.57-7.55 (d, *J* = 8.56 Hz, 2H, Ar-H), 7.48-7.46 (d, *J* = 8.52 Hz, 2H, Ar-H), 1.83-1.79 (m, 4H, Aliphatic-H), 1.67-1.62 (m, 3H, Aliphatic-H), 1.41-1.30 (m, 4H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 161, 147.1, 146.2, 138, 132.5, 132, 131.5, 131.1, 130.5, 130.1, 129.8, 129.1, 128.6, 128.3, 127.7, 122.68, 122.2, 70.4, 34.4, 25.7, 25.7, 25.7, 24.5; HRMS (EI) *m/z* calcd for $C_{23}H_{20}BrClN_4S$: 498.0281; found 498.0285.

5.5.8 6-(4-bromophenyl)-2-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl yl)methylene)cyclopropanamine 6h.

Yellowish green crystal; Yield 62%, mp. 201-203°C; IR [ATR, ν_{max}, cm^{-1}]: 3008.4 (Ar C-H), 2934.1 (C=C-H), 1605.4 (CH=N), 722 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 7.97 (s, 1H, CH=N), 7.96-7.77 (d, *J* = 8.80 Hz, 2H, Ar-H), 7.68-7.66 (d, *J* = 8.44 Hz, 2H, Ar-H), 7.51-7.49 (d, *J* = 8.52 Hz, 2H, Ar-H), 6.99-6.96 (d, *J* = 8.76 Hz, 2H, Ar-H), 3.86 (s, 3H, Ar-OCH_3), 2.14 (s, 1H, Aliphatic-H), 1.80 (br s, 4H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 162.4, 161.6, 145.3, 145.1, 141.7, 133.9, 132.9, 131.8, 131.6, 129.2, 128.3, 126.5, 122.7, 121.2, 114.7, 114.5, 109.4, 55.5. 34.2, 10.6, 10.6; HRMS (EI) *m/z* calcd for $C_{21}H_{17}BrN_4OS$: 452.0306; found 452.0310.

`

5.5.9 6-(4-bromophenyl)-2-(4-iodophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)cyclopropanamine 6i.

Yellowish green crystal; Yield 57%, mp. 203-205°C; IR [ATR, ν_{max}, cm^{-1}]: 3138.8 (Ar C-H), 2961.2 (C=C-H), 1581.2 (CH=N), 729.8 (C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.00 (s, 1H, CH=N), 7.85-7.83 (d, *J* = 8.48 Hz, 2H, Ar-H), 7.69-7.67 (d, *J*= 8.48 Hz, 2H, Ar-H), 7.58-7.56 (d, *J* = 8.48 Hz, 2H, Ar-H),7.52-7.50 (d, *J* = 8.48 Hz, 2H, Ar-H), 1.76 (br s, 4H, Aliphatic-H)1.23 (s, 1H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 160.7, 145.7, 145.2, 138.5, 138.5, 132.6, 131.8, 131.8, 131.6, 129.6, 129.1, 129.1, 128, 126.6, 121.5, 109.5, 98.3, 30.9, 10.3, 10.3; HRMS (EI) *m/z* calcd for $C_{20}H_{14}BrIN_4S$: 547.9167; found 547.9171.

5.5.10 6-(4-bromophenyl)-2-(4-iodophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)cyclohexanamine 6j.

Pale green crystal; Yield 44%, mp. 239-241°C; IR [ATR, ν_{max}, cm^{-1}]: 2918.3 (Ar C-H), 2848.3 (C=C-H), 1635.6 (CH=N), 764.7(C-Br); ^{1}H NMR [400 MHz, $CDCl_3$, δ ppm]: 8.62 (s, 1H, CH=N), 7.93-7.91 (d, *J* = 8.48 Hz, 2H, Ar-H), 7.84-7.82 (d, *J* = 8.48 Hz, 2H, Ar-H), 7.61-7.60 (d, *J* = 8.42 Hz, 2H, Ar-H), 7.56-7.54 (2H, Ar-H), 1.86-1.79 (m, 4H, Aliphatic-H) 1.67-1.62 (m, 3H, Aliphatic-H) 1.41-1.21(m, 4H, Aliphatic-H); ^{13}C NMR [101 MHz, $CDCl_3$, δ ppm]: 161.2, 147, 146.4, 145.2, 138.5, 138.4, 132.5, 132, 131.4, 130.4, 130.1, 129.5, 128.3, 128.2, 122.6, 122.2, 98.4, 70.4, 34.4, 30.9, 29.7, 25.7, 24.5; HRMS (EI) *m/z* calcd for $C_{23}H_{20}BrIN_4S$: 589.9637; found 589.9641.

5.6 Biological activity

5.6.1 In vitro evaluation of antimicrobial activity

The chalcone (**5a-o**) and Schiff base (**6a-j**) derivatives of imidazo[2,1-*b*]- 1,3,4 thiadiazole were further assessed for antimicrobial activity against panel of bacterial and fungal strains by following earlier reported MIC assay method using resazurin dye [36-38].

`

5.6.2 Microorganism used

Standard cultures of two gram +ve [*Staphylococcus aureus* ATCC25923, *Bacillus subtilis* ATCC6051], two gram –ve [*Escherichia coli* ATCC35218, *Pseudomonas aeruginosa* ATCC27853], three fungal strains [*Candida albicans* ATCC90028, *Cryptococcus neoformans* ATCC66031 and *Aspergillus niger* ATCC16404] and two clinical isolates of [*Candida albicans* and *Cryptococcus neoformans*] were used for the antibacterial and antifungal activity respectively. Culturing and subculturing (one day prior to testing) of these microorganisms was carried out at the department of microbiology, Inkosi Albert Luthuli hospital, Durban, South Africa. Subcultering of these microorganisms were used in this assay.

5.6.3 In vitro evaluation of antitubercular activity

The Anti-TB activity of the synthesized compounds was determined by measuring bacterial growth after 5 d in the presence of test compounds. Compounds were prepared as 10-point two-fold serial dilutions in DMSO and diluted into 7H9-Tw-OADC medium in 96-well plates with a final DMSO concentration of 2%. The highest concentration of compound was 200 µM where compounds were soluble in DMSO at 10 mM. For compounds with limited solubility, the highest concentration was 50X less than the stock concentration e.g. 100 µM for 5 mM DMSO stock, 20 µM for 1 mM DMSO stock. For potent compounds, assays were repeated at lower starting concentrations. Each plate included assay controls for background (medium/DMSO only, no bacterial cells), zero growth (100 µM rifampicin) and maximum growth (DMSO only), as well as a rifampicin dose response curve. Plates were inoculated with *M. tuberculosis* and incubated for 5 days: growth was measured by OD_{590} and fluorescence (Ex 560/Em 590) using a BioTek™ Synergy 4 plate reader. Growth was calculated separately for OD_{590} and RFU [39-41].

`

Acknowledgment

The authors sincerely thank College of Health Science, University of KwaZulu-Natal, Durban, South Africa and the National Research Foundation (NRF) for funding this project. We are also grateful to National Health laboratory services (NHLS), Inkosi Albert Luthuli Central Hospital (Durban, South Africa) for performing the antimicrobial activity as well as the Infectious Disease Research Institute (IDRI), National Institute of Allergy and Infectious Diseases (NIAID) screening program, Bethesda, MD, USA for carrying out the antitubercular testing. The authors would also like to acknowledge Mr. Dilip Jagjivan (School of Chemistry and Physics, UKZN, South Africa) for NMR spectral data.

`

References

[1] G.D. Brown, D.W. Denning, S.M. Levitz, Science, 336 (2012) 647.

[2] D.P. Kontoyiannis, R.E. Lewis, Lancet, 359 (2002) 1135-1144.

[3] K. Tripathi, V. Mor, N.K. Bairwa, M. Del Poeta, B.K. Mohanty, Front Microbiol, 3 (2012) 187.

[4] R. Velagapudi, Y.P. Hsueh, S. Geunes-Boyer, J.R. Wright, J. Heitman, Infect Immun, 77 (2009) 4345-4355.

[5] C.C. Lai, C.K. Tan, Y.T. Huang, P.L. Shao, P.R. Hsueh, J Infect Chemother, 14 (2008) 77-85.

[6] B.J. Park, K.A. Wannemuehler, B.J. Marston, N. Govender, P.G. Pappas, T.M. Chiller, AIDS, 23 (2009) 525-530.

[7] K. Voelz, R.C. May, Eukaryot Cell, 9 (2010) 835-846.

[8] T.S. Harrison, Clin Infect Dis, 48 (2009) 1784-1786.

[9] R.E. Lewis, Mayo Clin Proc, 86 (2011) 805-817.

[10] T.F. Patterson, Lancet, 366 (2005) 1013-1025.

[11] G. Mazzone, F. Bonina, G. Puglisi, R.R. Arrigo, C. Cosentino, G. Blandino, Farmaco Sci, 37 (1982) 685-700.

[12] Y. Luo, S. Zhang, Z.-J. Liu, W. Chen, J. Fu, Q.-F. Zeng, H.-L. Zhu, Euro J Med Chem, 64 (2013) 54-61.

[13] B. Chandrakantha, A.M. Isloor, P. Shetty, H.K. Fun, G. Hegde, Euro J Med Chem, 71 (2014) 316-323.

[14] B. Chaturvedi, N. Tiwari, Nizamuddin, Ind. J. Chem, 28B (1989) 358–361.

[15] V.P. Arya, F. Fernandes, V. Sudarsanam, Ind. J. Chem, 10 (1972) 598-601.

[16] I.T. Barnish, P.E. Cross, R.P. Dickinson, B. Gadsby, M.J. Parry, M.J. Randall, I.W. Sinclair, J Med Chem, 23 (1980) 117-121.

[17] I.A. Khazi, C.S. Mahajanshetti, A.K. Gadad, A.D. Tarnalli, C.M. Sultanpur, Arzneimitt, 46 (1996) 949-952.

[18] H.M. Patel, M.N. Noolvi, A. Goyal, B.S. Thippeswamy, Eur J Med Chem, 65 (2013) 119-133.

[19] E. Abignente, F. Arena, E. Luraschi, C. Saturnino, E. Marmo, M. Cazzola, F. Rossi, E. Lampa, Farmaco Sci, 40 (1985) 190-199.

[20] A.K. Gadad, M.B. Palkar, K. Anand, M.N. Noolvi, T.S. Boreddy, J. Wagwade, Bioorg Med Chem, 16 (2008) 276-283.

`

[21] A. Marin, N. Valls, F.J. Berenguer, M.T. Alonso, A. Ramon Martinez, M. Mercedes Martinez, J. Elguero, Farmaco, 47 (1992) 63-75.

[22] I.A.M. Khazi, A.K. Gadad, R.S. Lamani, B.A. Bhongade, Tetrahedron, 67 (2011) 3289-3316.

[23] C. Viegas-Junior, A. Danuello, V. da Silva Bolzani, E.J. Barreiro, C.A. Fraga, Curr Med Chem, 14 (2007) 1829-1852.

[24] C. Lazar, A. Kluczyk, T. Kiyota, Y. Konishi, J Med Chem, 47 (2004) 6973-6982.

[25] K.V. Sashidhara, A. Kumar, M. Kumar, J. Sarkar, S. Sinha, Bioorg Med Chem Lett, 20 (2010) 7205-7211.

[26] C. Karthikeyan, V.R. Solomon, H. Lee, P. Trivedi, Biomed Prevent Nutr, 3 (2013) 325-330.

[27] R.A. Rane, N.U. Sahu, S.D. Gutte, A.A. Mahajan, C.P. Shah, P. Bangalore, Eur J Med Chem, 63 (2013) 793-799.

[28] X.F. Liu, C.J. Zheng, L.P. Sun, X.K. Liu, H.R. Piao, Eur J Med Chem, 46 (2011) 3469-3473.

[29] P. Rathelot, P. Vanelle, M. Gasquet, F. Delmas, M.P. Crozet, P. Timon-David, J. Maldonado, Eur J Med Chem, 30 (1995) 503-508.

[30] D. Sriram, P. Yogeeswari, N.S. Myneedu, V. Saraswat, Bioorg Med Chem Lett, 16 (2006) 2127-2129.

[31] I.V. Drapak, B.S. Zimenkovsky, R.B. Lesyk, D.V. Atamanyuk, U.B. Tchulovska, I.O. Nektegajev, Farm. Zh, 21 (2008) 57-62.

[32] M. Maaland , L. Guardabassi, Vet Microbiol, 151 (2011) 396-399.

[33] S.G. Alegaon, K.R. Alagawadi, P.V. Sonkusare, S.M. Chaudhary, D.H. Dadwe, A.S. Shah, Bioo Med Chem Lett, 22 (2012) 1917-1921.

[34] A.K. Gadad, M.N. Noolvi, R.V. Karpoormath, Bioorg Med Chem, 12 (2004) 5651-5659.

[35] K.R. Alagawadi, S.G. Alegaon, Arab J Chem, 4 (2011) 465-472.

[36] C.M. Mann, J.L. Markham, J App Microbiol, 84 (1998) 538-544.

[37] A. Espinel-Ingroff, A. Fothergill, M. Ghannoum, E. Manavathu, L. Ostrosky-Zeichner, M. Pfaller, M. Rinaldi, W. Schell, T. Walsh, J Clin Microbiol, 43 (2005) 5243-5246.

[38] M. Jameel, M. Islamuddin, A. Ali, F. Afrin, M. Ali, Comp Altern Med, 14 (2014) 98.

[39] J. Ollinger, M.A. Bailey, G.C. Moraski, A. Casey, S. Florio, T. Alling, M.J. Miller, T. Parish, A, PLoS One, 8 (2013) 60531.

[40] P. Carroll, L.J. Schreuder, J. Muwanguzi-Karugaba, S. Wiles, B.D. Robertson, J. Ripoll, T.H. Ward, G.J. Bancroft, U.E. Schaible, T. Parish, PLoS One, 5 (2010) 9823.

`

[41] A. Zelmer, P. Carroll, N. Andreu, K. Hagens, J. Mahlo, N. Redinger, B.D. Robertson, S. Wiles, T.H. Ward, T. Parish, J. Ripoll, G.J. Bancroft, U.E. Schaible, J Antimicrob Chemother, 67 (2012) 1948-1960.

`

List of captions

Tables

Table 1. Anti-fungal, antibacterial and anti-tubercular activity of a novel series of chalcone (**5a-o**) and Schiff base (**6a-j**) analogues of imidazo[2,1-*b*]-1,3,4thiadiazole

Figures

F**ig. 1.** Design of various chalcone (**5a-o**) and Schiff base (**6a-j**) analogues of imidazo[2,1-*b*]-1,3,4-thiadiazole by molecular hybridization approach

Schemes

Scheme 1. The synthetic outline for the synthesis of novel series of chalcone (**5a-o**) and Schiff base (**6a-j**) analogues of imidazo[2,1-*b*]-1,3,4-thiadiazole; Reagents and conditions: (**a**) Thiosemicarbazide, POCl3, reflux, 4 h, basify 40% NH4OH; (**b**) Thiosemicarbazide, FeCl3, Sodium citrate, citric acid, reflux, 1 h, basify, 40% NH4OH; (c) 4-Bromo phenacylbromide, DMF, heating, 12-16 h; (**d**) DMF, POCl3, 0 °C, stir, 90 °C, 6 h, Na2CO316 h; (**e**) Aryl/Heteroaryl ketones, Ethanol, 10% NaOH, stir, RT, 6-10 h; (**f**) Cyclopropylamine or Cyclohexylamine, glacial acetic acid MW 20-30 min at 150 W.

`

Table 1. Anti-fungal, antibacterial and anti-tubercular activity of a novel series of chalcone (**5a-o**) and Schiff base (**6a-j**) analogues of imidazo[2,1-*b*]-1,3,4thiadiazole.

Code	Structure	*C. albicans*[a] ATCC90028	*C. albicans*[a,c] (Clinical Isolate)	*C. neoformans*[a] ATCC66031	*C. neoformans*[a,c] (Clinical Isolate)	*A. niger*[a] ATCC16404	*S. aureus*[a] ATCC25923	*B. subtilis*[a] ATCC6051	*E. coli*[a] ATCC35218	*P. aeruginosa*[a] ATCC27853	*M. tuberculosis*[b] $H_{37}Rv$
5a		200	>200	**1.56**	**6.25**	>200	200	>200	>200	>200	>20
5b		200	>200	**1.56**	**12.5**	>200	100	>200	>200	>200	>20
5c		>200	>200	**3.125**	**12.5**	>200	>200	>200	>200	>200	>20
5d		>200	>200	12.5	12.5	>200	>200	>200	100	>200	>20
5e		50	>200	50	100	>200	200	>200	>200	>200	>20
5f		50	>200	200	200	>200	>200	>200	>200	>200	>20
5g		>200	>200	25	200	>200	>200	>200	>200	>200	>20

`

Table 1. Continue

Code	Structure	*C. albicans*[a] ATCC90028	*C. albicans*[a,c] (Clinical Isolate)	*C. neoformans*[a] ATCC66031	*C. neoformans*[a,c] (Clinical Isolate)	*A. niger*[a] ATCC16404	*S. aureus*[a] ATCC25923	*B. subtilis*[a] ATCC6051	*E. coli*[a] ATCC35218	*P. aeruginosa*[a] ATCC27853	*M. tuberculosis*[b] $H_{37}Rv$
5h		25	>200	25	100	>200	>200	>200	>200	>200	>20
5i		200	>200	6.25	6.25	>200	>200	>200	>200	>200	>20
5j		>200	>200	6.25	12.5	>200	>200	>200	>200	>200	>20
5k		50	>200	**3.125**	**6.25**	>200	>200	200	>200	>200	>20
5l		25	>200	12.5	12.5	>200	>200	>200	>200	>200	>20
5m		50	>200	**3.125**	**12.5**	>200	>200	>200	200	>200	>20
5n		200	>200	**1.56**	**3.125**	>200	>200	>200	200	>200	>20

`

Table 1. Continue

Code	Structure	*C. albicans*[a] ATCC90028	*C. albicans*[a,c] (Clinical Isolate)	*C. neoformans*[a] ATCC66031	*C. neoformans*[a,c] (Clinical Isolate)	*A. niger*[a] ATCC16404	*S. aureus*[a] ATCC25923	*B. subtilis*[a] ATCC6051	*E. coli*[a] ATCC35218	*P. aeruginosa*[a] ATCC27853	*M. tuberculosis*[b] $H_{37}Rv$
5o		100	>200	25	200	>200	>200	>200	>200	>200	>20
6a		25	50	100	200	100	200	>200	200	50	ND
6b		50	50	100	200	50	200	>200	200	50	ND
6c		25	50	100	>200	100	200	>200	200	50	ND
6d		12.5	25	100	>200	100	200	>200	200	50	ND
6e		25	50	100	>200	100	200	200	200	50	ND
6f		25	50	100	200	100	200	200	200	50	ND

`

Code	Structure	*C. albicans*[a] ATCC90028	*C. albicans*[a,c] (Clinical Isolate)	*C. neoformans*[a] ATCC66031	*C. neoformans*[a,c] (Clinical Isolate)	*A. niger*[a] ATCC16404	*S. aureus*[a] ATCC25923	*B. subtilis*[a] ATCC6051	*E. coli*[a] ATCC35218	*P. aeruginosa*[a] ATCC27853	*M. tuberculosis*[b] $H_{37}Rv$
6g		50	50	100	>200	100	200	200	200	50	ND
6h		25	50	100	>200	100	200	200	200	25	ND
6i		25	50	100	>200	100	200	200	200	50	ND
6j		25	50	100	>200	100	200	200	200	50	ND
	Amphotericin B	**0.25**	**25**	**1-2**	**1-2**	**1.95**	**-**	**-**	**-**	**-**	**-**
	Moxcillin	**-**	**-**	**-**	**-**	**-**	**<0.39**	**<0.39**	**<0.39**	**<0.39**	**-**
	Rifampicin	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**0.0067**

[a] MIC in µg/mL.
[b] MIC in µM/mL.
[c] well characterized stored clinical isolates obtained from department of microbiology, Inkosi Albert Luthuli hospital, Durban, South Africa.



I

Anti Fungal
MIC = 6.25 µg/mL *C.albicans*
12.5 µg/mL *C.tropicatis*
6.25 µg/mL *C.neoformans*

II

Anticonvulsant
Oral ED_{50}=2.6 mg/kg

III

Anti inflammatory
inhibition of COX-2=80.6 %

IV

Anti cancer
OVCAR-3 GI_{50}= 5.51 µM
MCF-7 GI_{50}= 4.51 µM
KL-60 GI_{50}= 4.50 µM



V

Anticancer cervical
carcinoma IC_{50} = 3.59 µM[



VI

Anticancer
MDA-MB231 GI_{50}= 8.54 µM
MDA-MB468 GI_{50}= 4.76µM
MCF7 GI_{50}= 3.95 µM



VII

Anticancer
MCF7 IC_{50}= 3.12 µM
WRL68 IC_{50}=1.91µM
PAI IC_{50} =2.85 µM



VIII

Anti bacterial
MIC= 1µg/ml *S. aureus*



Designed analogues of Chalcones



IX

Anti malarial
MIC=0.7 µg/mL *P. falciparum*



X

Anti viral
EC_{50}< 6 µM HIV-1



XI

Antitubercular activity
(*M. tuberculosis* $H_{37}Rv$)
MIC = 0.03 mg/ml



XII

Nitrofurantoin
Anti-infective agent



Designed analogues of Schiff bases

Fig. 1 Design of various chalcone (**5a-o**) and Schiff base (**6a-j**) analogues of imidazo[2,1-*b*]-1,3,4-thiadiazole by molecular hybridization approach.



Scheme 1. The synthetic outline for the synthesis of novel series of chalcone (**5a-o**) and Schiff base (**6a-j**) analogues of imidazo[2,1-*b*]-1,3,4-thiadiazole; Reagents and conditions: (**a**) Thiosemicarbazide, POCl3, reflux, 4 h, basify 40% NH4OH; (**b**) Thiosemicarbazide, FeCl3, Sodium citrate, citric acid, reflux, 1 h, basify, 40% NH4OH; (c) 4-Bromo phenacylbromide, DMF, heating, 12-16 h; (**d**) DMF, POCl3, 0 °C, stir, 90 °C, 6 h, Na2CO316 h; (**e**) Aryl/Heteroaryl ketones, Ethanol, 10% NaOH, stir, RT, 6-10 h; (**f**) Cyclopropylamine or Cyclohexylamine, glacial acetic acid MW 20-30 min at 150 W.

Highlights

- Two series of imidazo[2,1-*b*]-1,3,4-thiadiazole derivatives were synthesized.
- Compounds **5a**, **5b** and **5n** exhibited promising activity against *C. neoformans.*
- Compound **5n** was found to be active against clinical isolates of *C. neoformans.*
- Moderate antibacterial and antimycobacterial activity was observed.

Supplementary Information

Novel imidazo[2,1-*b*]-1,3,4-thiadiazoles as Promising Antifungal Agents Against Clinical Isolate of *C. Neoformans*

Wesam S. Alwan[a], Mahesh B. Palkar[a], Rajesh A. Rane[a], Harun M. Patel[a], Mahamadhanif S. Shaikh[a], Afsana Kajee[a,b], Koleka P. Mlisana[b], Rajshekhar Karpoormath[a*.]

[a]*Department of Pharmaceutical Chemistry, Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban – 4000, South Africa.*

[b]*Departemnt of Microbiology, National Health laboratory services (NHLS), Inkosi Albert Luthuli Central Hospital (Durban, South Africa).*

***Corresponding author**

E-mail: karpoormath@ukzn.ac.za, rvk2006@gmail.com

Tel no.: +27(0)312607179, +27721107207; Fax No.:+27(0)312607792

Spectral data



Spectrum 1. ^{1}H NMR spectrum of compound (**5a**)



Spectrum 2. ^{13}C NMR spectrum of compound (**5a)**



Spectrum 3. ^{1}H NMR spectrum of compound (**5b**)



Spectrum 4. ^{13}C NMR spectrum of compound (**5b)**



Spectrum 5.[1]H NMR spectrum of compound **(5c)**



Spectrum 6.[13]C NMR spectrum of compound **(5c)**



Spectrum 7.[1]H NMR spectrum of compound **(5d)**



Spectrum 8.[13]C NMR spectrum of compound **(5d)**



Spectrum 9. ^{1}H NMR spectrum of compound **(5e)**



Spectrum 10.^{13}C NMR spectrum of compound **(5e)**



Spectrum 11. ^{1}H NMR spectrum of compound **(5f)**



Spectrum 12.^{13}C NMR spectrum of compound **(5f)**



Spectrum 13. ^{1}H NMR spectrum of compound **(5g)**



Spectrum 14. ^{13}C NMR spectrum of compound **(5g)**



Spectrum 15. ^{1}H NMR spectrum of compound **(5h)**



Spectrum 16.^{13}C NMR spectrum of compound**(5h)**



Spectrum 17. ^{1}H NMR spectrum of compound **(5i)**



Spectrum 18. ^{13}C NMR spectrum of compound**(5i)**



Spectrum 19. ^{1}H NMR spectrum of compound **(5j)**



Spectrum 20. ^{13}C NMR spectrum of compound**(5j)**



Spectrum 21.[1]H NMR spectrum of compound **(5k)**



Spectrum 22.[13]C NMR spectrum of compound **(5k)**



Spectrum 23.[1]H NMR spectrum of compound **(5l)**



Spectrum 24.[13]C NMR spectrum of compound **(5l)**



Spectrum 25. ^{1}H NMR spectrum of compound **(5m)**



Spectrum 26. ^{13}C NMR spectrum of compound **(5m)**



Spectrum 27. ^{1}H NMR spectrum of compound **(5n)**



Spectrum 28. ^{13}C NMR spectrum of compound **(5n)**



Spectrum 29.[1]**H NMR spectrum of compound (5o)**



Spectrum 30. [13]C NMR spectrum of compound (**5o)**



Spectrum 31. ^{1}H NMR spectrum of compound **(6a)**



Spectrum 32. ^{13}C NMR spectrum of compound **(6a)**



Spectrum 33. ^{1}H NMR spectrum of compound **(6b)**



Spectrum 34. ^{1}H NMR spectrum of compound **(6b)**



Spectrum 35. ^{1}H NMR spectrum of compound **(6c)**



Spectrum 36. ^{13}C NMR spectrum of compound **(6c)**



Spectrum 37. ^{1}H NMR spectrum of compound **(6d)**



Spectrum 38. ^{13}C NMR spectrum of compound **(6d)**



Spectrum 39. ^{1}H NMR spectrum of compound **(6e)**



Spectrum 40. ^{13}C NMR spectrum of compound **(6e)**



Spectrum 41. ^{1}H NMR spectrum of compound **(6f)**



Spectrum 42. ^{13}C NMR spectrum of compound **(6f)**



Spectrum 43. ^{1}H NMR spectrum of compound **(6g)**



Spectrum 44. ^{13}C NMR spectrum of compound **(6g)**



Spectrum 45. ^{1}H NMR spectrum of compound (**6h)**



Spectrum 46. ^{13}C NMR spectrum of compound **(6h)**



Spectrum 47. ^{1}H NMR spectrum of compound **(6i)**



Spectrum 48. ^{13}C NMR spectrum of compound **(6i)**



Spectrum 49. ^{1}H NMR spectrum of compound (**6j)**



Spectrum 50. ^{13}C NMR spectrum of compound **(6j)**

In vitro evaluation of antimicrobial activity

Preparation of medium

The nutrient medium was prepared by dissolving 22 g of Muller-Hinton Broth containing (Acid Hydrolysate of Casein, Beef Extract and Starch) in 1 L of double distilled water. The pH of this medium was adjusted to 7.4 ± 0.1 and sterilized by autoclave for 15 min at 121°C. The solution was allowed to cool and stored at a temp of 4°C. Sterility check was performed by incubating un-inoculated media in an aerobic incubator at 37 °C for 18-24 h. For antifungal activity, RPMI 1640 medium with L-glutamine and 0.165 M MOPS and without sodium bicarbonate (Lonza) was used.

Preparation of test compounds (stock solution and working standard)

An accurately weighed quantity (4.000 mg) of the synthesized compounds and standard drugs were dissolved in 1 ml of DMSO to give stock solution (4000 µg/ml). Further, 100 µl of stock solution was diluted with 900 µl of double distilled water to afford working standard solution (400 µg/ml).

Preparation of inoculums

One day prior to testing one or more identical colonies of microorganisms were suspended in 4.5 ml sterile double distilled water. The inoculates were adjusted to 0.5 McFarland standard (1.5×10^8 cfu/ml). A density check turbid meter was used to ensure that the inoculum was a 0.5 McFarland standard.

Broth micro-dilution method

The preliminary *in vitro* antimicrobial activity for the newly synthesized title compounds (**5a-o** and **6a-j**) was evaluated using the broth micro-dilution method. 100 µl of sterile double distilled water was added to all outer-perimeter wells of a 96-well microliter plates to minimize evaporation of the medium in the test wells during incubation. To the remaining test wells 100 µl of MHB was added. Two fold serial dilutions of the test compounds and

standard drugs (Moxicillin and Amphotericin B) were made directly on the microplate using MHB.

The compounds were tested at final concentration of (200, 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39 µg/ml). Finally, 10 µl of the freshly prepared bacterial or fungal inoculum was added to the wells. The microliter plates were covered and sealed with parafilm and incubated at 37 ± 1 ºC for 24 h. After this, 10 µl of freshly prepared resazurin (0.4 mg/ml) was added to the test wells and incubated further for 5h. MIC was determined as a blue colour in the test well was interpreted as no bacterial growth and a pink colour was scored as growth. The MIC was thus defined at the lowest drug concentration that prevented a colour change from blue to pink. This experiment was conducted in duplicate and the average MIC values in µg/ml.